CVS Q2 2026 earnings beat estimates as Aetna medical benefit ratio declines
CVS raised its 2026 outlook after reporting a second-quarter beat, while Aetna’s medical benefit ratio fell to 87.4%.
By Maya Okafor · Markets Writer
· 3 min read
CVS Q2 2026 earnings topped Wall Street expectations, and the company again lifted its full-year outlook. For investors, the report showed broad revenue growth and a lower medical benefit ratio at Aetna, though CVS said elevated health-care costs and economic risks still warrant caution.
CVS reported Aug. 5 that second-quarter revenue rose 7.3% from a year earlier to $106.1 billion. Adjusted earnings were $2.58 a share, ahead of the $1.85 consensus estimate from LSEG cited by CNBC, while revenue exceeded the $100.11 billion analyst estimate. CVS reported GAAP, or generally accepted accounting principles, diluted earnings per share of $2.31 and net income of $2.995 billion. Adjusted earnings exclude certain items and are a separate measure from the company’s GAAP results.
The company raised its 2026 adjusted earnings outlook to $7.90 to $8.10 a share, from $7.30 to $7.50. It also lifted GAAP diluted EPS guidance to $6.84 to $7.04 from $6.24 to $6.44, raised its revenue target to at least $414 billion from at least $405 billion, and increased expected operating cash flow to at least $11.5 billion from at least $9.5 billion, according to CVS’s quarterly results release.
What drove CVS’s Q2 2026 earnings beat?
All three operating segments recorded revenue growth, CVS said. Its Health Care Benefits business, which includes Aetna, posted $37.538 billion in revenue, up 3.5% from a year earlier. Health Services revenue climbed 11.5% to $51.8 billion, while Pharmacy & Consumer Wellness generated $33.82 billion, slightly above the prior-year period, according to CVS and CNBC.
CVS said the guidance increase reflects increases in its Health Care Benefits and Pharmacy & Consumer Wellness businesses. Within Health Care Benefits, adjusted operating income rose 85.5% to $2.426 billion. The company attributed that year-over-year change primarily to stronger underlying performance in its Government business and the absence of a $471 million premium deficiency reserve recorded in Group Medicare Advantage during the comparable 2025 quarter.
A premium deficiency reserve is a liability an insurer may record when expected future premiums may not cover anticipated claims and expenses. Its absence makes the year-over-year comparison more favorable, alongside the company’s stated improvement in Government-business performance.
Why does Aetna’s medical benefit ratio matter?
Aetna’s medical benefit ratio declined to 87.4% from 89.9% a year earlier. The ratio measures total medical expenses paid relative to premiums collected. A lower ratio generally means an insurer has retained more premium revenue after medical expenses, which can support profitability. CNBC reported the figure also came in below the 89.8% expectation compiled by StreetAccount.
CVS said the lower ratio reflected improved underlying Government-business performance and the lack of the prior-year reserve. Medical membership was 26 million as of June 30, unchanged from March 31, according to the company.
Management did not present the results as an end to cost pressure. CVS said it remains cautious for the rest of 2026 because cost trends remain elevated and broader economic conditions could create headwinds.
This story draws on original reporting from CNBC.
